US EditionKelyniam Global Announces Q1 2025 Financial Results and Strategic Partnership
- On May 12, 2025, from Canton, Connecticut, Kelyniam Global, Inc. reported its financial performance for the first quarter of 2025 and announced the establishment of a new partnership with Singapore-based Osteopore Ltd., involving a distribution deal set to last three years.
- The company encountered difficulties in the quarter due to seasonal fluctuations, the scheduling of surgeries, and postponed revenue recognition, but addressed these issues by expanding its sales leadership with the addition of Alex Rivero as the new National Sales Director.
- Kelyniam reported a 34.7% decrease in total revenue to $624,910 and a 36.6% drop in gross margin to $470,940, resulting in a $140,556 operating loss compared to profit in Q1 2024.
- In response to recent difficulties, CEO Ross Bjella highlighted the expansion of the sales team by bringing Alex Rivero on board as National Sales Director and indicated intentions to add up to 10 new distributors during 2025.
- The partnership with Osteopore, a Singapore-based ASX-listed company specializing in bioresorbable implants, aims to enhance Kelyniam's regenerative product offerings and market position in the U.S.
Insights by Ground AI
Does this summary seem wrong?
90 Articles
90 Articles
Daily News-Record+89 Reposted by 89 other sources
Kelyniam Global Announces Q1 2025 Financial Results and Strategic Partnership
CANTON, Conn., May 12, 2025 /PRNewswire/ -- Kelyniam Global, Inc. (OTC: KLYG), a leading manufacturer of custom cranial and craniofacial implants, today announced its financial results for the first quarter ended March 31, 2025, and highlighted a new partnership to…
Coverage Details
Total News Sources90
Leaning Left10Leaning Right11Center28Last UpdatedBias Distribution57% Center
Bias Distribution
- 57% of the sources are Center
57% Center
L 20%
C 57%
R 22%
Factuality
To view factuality data please Upgrade to Premium
